DK2363140T3 - Antisekretorisk protein til anvendelse i behandlingen af kompartmentsyndrom - Google Patents
Antisekretorisk protein til anvendelse i behandlingen af kompartmentsyndrom Download PDFInfo
- Publication number
- DK2363140T3 DK2363140T3 DK10188590.3T DK10188590T DK2363140T3 DK 2363140 T3 DK2363140 T3 DK 2363140T3 DK 10188590 T DK10188590 T DK 10188590T DK 2363140 T3 DK2363140 T3 DK 2363140T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- fragment
- homologue
- antisecretory
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
Claims (16)
1. Antisekretionsfaktor (AF) -protein, en homolog og/eller et fragment deraf med antisekretorisk aktivitet, og/eller et farmaceutisk aktivt salt deraf, til anvendelse i behandlingen og/eller forebyggelsen af et kompartmentsyndrom forårsaget af tilstedeværelsen af en godartet og/eller en ondartet tumor i et legeme.
2. Antisekretionsfaktor (AF) -protein, en homolog og/eller et fragment deraf med antisekretorisk aktivitet, og/eller et farmaceutisk aktivt salt deraf, til anvendelse ifølge krav 1, hvor kompartmentsyndromet er forårsaget af behandlingen af en tumor og/eller nærliggende strukturer.
3. Antisekretionsfaktor (AF) -protein til anvendelse ifølge krav 1, hvor antisekretionsfaktor (AF) -proteinet svarer til en aminosyresekvens som vist i SEQ ID NO 6:, eller en homolog og/eller et fragment deraf omfattende aminosyrer 38-42 af SEQ ID NO: 6, og/eller et farmaceutisk aktivt salt deraf.
4. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge krav 1, bestående af en sekvens ifølge den følgende formel
hvor XI er I, aminosyrer 1-35 af SEQ ID NO: 5, eller er fraværende, X2 er H, R eller K, X3 er S eller L, X4 er T eller A, X5 er aminosyrer 43-46, 43-51, 43-80 eller 43-163 af SEQ ID NO: 6, eller er fraværende, og/eller et farmaceutisk aktivt salt deraf.
5. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge krav 1, hvor fragmentet omfatter en aminosyresekvens som vist i SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID N0:4, eller SEQ ID NO:5, og/eller et farmaceutisk aktivt salt deraf.
6. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 1-4, hvor tumoren er en primær tumor eller en metastase.
7. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor kompartmentsyndromet er forårsaget af bivirkninger forårsaget af behandling af tumoren med røntgen, højenergi stråling, lokal afkøling, lokal opvarmning, lysterapi og/eller lægemidler anvendt til behandlingen af tumoren.
8. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af de foregående krav, hvor behandlingen af kompartmentsyndromet forbedrer effektiviteten af cancerterapi ved at sænke det interstitielle tryk.
9. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af de foregående krav, hvor antisekretionsfaktor (AF) -proteinet, en homolog, og/eller fragment deraf er til stede i en farmaceutisk sammensætning og/eller en medicinsk fødevare.
10. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge krav 9, hvor den farmaceutiske sammensætning og/eller den medicinske fødevare omfatter to eller flere antisekretoriske proteiner, eller en homolog, og/eller fragment deraf ifølge et hvilket som helst af kravene 1-4.
11. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 9-10, hvor den farmaceutiske sammensætning yderligere omfatter en farmaceutisk acceptabel excipiens.
12. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 9-11, hvor den farmaceutiske sammensætning er formuleret til administration i en kropsåbning, intraokulært, intranasalt, oralt, lokalt, kutant, subkutant, intramuskulært og/eller systemisk.
13. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 9-12, hvor den farmaceutiske sammensætning er formuleret til administration som en spray, aerosol, inhalator eller ved hjælp af en forstøver.
14. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 9-13, hvor den farmaceutiske sammensætning er formuleret til systemisk administration til blodet med en indgivelsesdosis på 0,1 pg til 10 mg per kg kropsvægt og dag, fortrinsvis 1-1000 pg per kg kropsvægt og dag.
15. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af kravene 9-14, hvor administrationen udføres enten som en enkelt dosis eller som flere daglige indgivelser.
16. Antisekretionsfaktor (AF) -protein, eller en homolog og/eller et fragment deraf til anvendelse ifølge et hvilket som helst af de foregående krav, hvor det antisekretoriske protein er tilvejebragt i æggeblomme beriget med sådant antisekretorisk protein, og hvor det antisekretoriske protein fortrinsvis er tilvejebragt i æggeblommen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0600933 | 2006-04-27 | ||
| EP07748078A EP2040734B1 (en) | 2006-04-27 | 2007-04-27 | Antisecretory protein for use in the treatment of compartment syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2363140T3 true DK2363140T3 (da) | 2017-03-06 |
Family
ID=38655929
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10188590.3T DK2363140T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse i behandlingen af kompartmentsyndrom |
| DK07748080.4T DK2037950T3 (da) | 2006-04-27 | 2007-04-27 | Yderligere medicinske anvendelser af antisekretorisk protein |
| DK07748078.8T DK2040734T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07748080.4T DK2037950T3 (da) | 2006-04-27 | 2007-04-27 | Yderligere medicinske anvendelser af antisekretorisk protein |
| DK07748078.8T DK2040734T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8309513B2 (da) |
| EP (2) | EP2040734B1 (da) |
| JP (2) | JP5323682B2 (da) |
| KR (3) | KR101805973B1 (da) |
| CN (3) | CN101460187B (da) |
| AT (1) | ATE526031T1 (da) |
| AU (1) | AU2007244003B2 (da) |
| BR (2) | BRPI0710858A2 (da) |
| CA (1) | CA2650589C (da) |
| DK (3) | DK2363140T3 (da) |
| ES (3) | ES2472737T3 (da) |
| HK (1) | HK1131738A1 (da) |
| IL (1) | IL194774A (da) |
| MX (1) | MX2008013774A (da) |
| NZ (2) | NZ572256A (da) |
| PL (2) | PL2040734T3 (da) |
| RU (2) | RU2457853C2 (da) |
| SG (1) | SG171601A1 (da) |
| WO (1) | WO2007126363A2 (da) |
| ZA (2) | ZA200809116B (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2015767T3 (da) | 2006-04-27 | 2016-02-08 | Lantmännen As Faktor Ab | Anvendelse af antisekretorisk faktor til behandling af intraokulær hypertension |
| EP2037950B1 (en) * | 2006-04-27 | 2014-04-23 | Lantmännen AS-Faktor AB | Further medical uses of antisecretory protein |
| CN101460187B (zh) | 2006-04-27 | 2014-11-05 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白的进一步医疗应用 |
| US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US8901083B2 (en) | 2008-11-25 | 2014-12-02 | Temple University | Administration of angiocidin for the treatment of leukemia |
| JP5820277B2 (ja) * | 2009-02-11 | 2015-11-24 | ラントメネン・アーエス−ファクトール・アーベー | 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用 |
| MX2018000069A (es) | 2015-07-10 | 2018-03-16 | Lantmaennen As Faktor Ab | Proceso para producir yema de huevo con alto contenido de factor antisecretor 16. |
| KR102268955B1 (ko) * | 2016-07-18 | 2021-06-25 | 란트만넨 아스-팍토르 아베 | 항분비 인자 17 |
| CA3103164A1 (en) | 2018-06-28 | 2020-01-02 | Lantmannen Medical Ab | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |
| CN112770644A (zh) | 2018-09-28 | 2021-05-07 | 兰特门内保健食品公司 | 包含麦芽化小麦的可消耗产品 |
| CN112770643A (zh) | 2018-09-28 | 2021-05-07 | 兰特门内保健食品公司 | 包含麦芽化脱壳燕麦的可消耗产品 |
| WO2021191431A1 (en) | 2020-03-26 | 2021-09-30 | Lantmännen Functional Foods Ab | A consumable product comprising malted cereals for promoting recovery at physical activity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH682716A5 (de) * | 1992-01-13 | 1993-11-15 | Christian Fricker | Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung. |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| SE508609C2 (sv) * | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| SE9604251L (sv) | 1996-11-20 | 1997-12-22 | Svenska Lantmaennen Riksfoerbu | Födoämne som vid förtäring inducerar antisekretoriska proteiner |
| SE513496C2 (sv) * | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| US7662169B2 (en) * | 2000-09-05 | 2010-02-16 | Wittmann Dietmar H | Prosthesis and method for lowering abdominal pressure |
| GB0322645D0 (en) | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| EP2037950B1 (en) | 2006-04-27 | 2014-04-23 | Lantmännen AS-Faktor AB | Further medical uses of antisecretory protein |
| CN101460187B (zh) | 2006-04-27 | 2014-11-05 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白的进一步医疗应用 |
| WO2009052478A1 (en) * | 2007-10-19 | 2009-04-23 | Trustees Of Boston University | Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide |
-
2007
- 2007-04-27 CN CN200780014997.4A patent/CN101460187B/zh not_active Expired - Fee Related
- 2007-04-27 CA CA2650589A patent/CA2650589C/en active Active
- 2007-04-27 DK DK10188590.3T patent/DK2363140T3/da active
- 2007-04-27 KR KR1020147032781A patent/KR101805973B1/ko active IP Right Grant
- 2007-04-27 JP JP2009507631A patent/JP5323682B2/ja active Active
- 2007-04-27 WO PCT/SE2007/000413 patent/WO2007126363A2/en active Application Filing
- 2007-04-27 KR KR1020087029120A patent/KR20090045148A/ko active Search and Examination
- 2007-04-27 RU RU2008146731/15A patent/RU2457853C2/ru active
- 2007-04-27 PL PL07748078T patent/PL2040734T3/pl unknown
- 2007-04-27 BR BRPI0710858-3A patent/BRPI0710858A2/pt not_active Application Discontinuation
- 2007-04-27 ES ES07748080.4T patent/ES2472737T3/es active Active
- 2007-04-27 RU RU2008146734/15A patent/RU2465914C2/ru active
- 2007-04-27 BR BRPI0710794-3A patent/BRPI0710794A2/pt not_active IP Right Cessation
- 2007-04-27 KR KR1020147027241A patent/KR101757523B1/ko active IP Right Grant
- 2007-04-27 SG SG201102875-0A patent/SG171601A1/en unknown
- 2007-04-27 AT AT07748078T patent/ATE526031T1/de not_active IP Right Cessation
- 2007-04-27 CN CN201510082714.6A patent/CN104689299B/zh active Active
- 2007-04-27 AU AU2007244003A patent/AU2007244003B2/en active Active
- 2007-04-27 CN CN200780014998.9A patent/CN101437533B/zh active Active
- 2007-04-27 PL PL10188590T patent/PL2363140T3/pl unknown
- 2007-04-27 EP EP07748078A patent/EP2040734B1/en active Active
- 2007-04-27 MX MX2008013774A patent/MX2008013774A/es active IP Right Grant
- 2007-04-27 EP EP10188590.3A patent/EP2363140B1/en active Active
- 2007-04-27 ES ES10188590.3T patent/ES2615515T3/es active Active
- 2007-04-27 DK DK07748080.4T patent/DK2037950T3/da active
- 2007-04-27 NZ NZ572256A patent/NZ572256A/en not_active IP Right Cessation
- 2007-04-27 NZ NZ572257A patent/NZ572257A/en not_active IP Right Cessation
- 2007-04-27 ES ES07748078T patent/ES2374712T3/es active Active
- 2007-04-27 DK DK07748078.8T patent/DK2040734T3/da active
-
2008
- 2008-10-22 IL IL194774A patent/IL194774A/en active IP Right Grant
- 2008-10-23 ZA ZA200809116A patent/ZA200809116B/xx unknown
- 2008-10-23 ZA ZA200809114A patent/ZA200809114B/xx unknown
- 2008-10-27 US US12/289,389 patent/US8309513B2/en active Active
-
2009
- 2009-09-29 HK HK09108961.9A patent/HK1131738A1/xx not_active IP Right Cessation
-
2010
- 2010-11-02 JP JP2010245989A patent/JP5285043B2/ja active Active
-
2011
- 2011-02-11 US US13/025,702 patent/US8389468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2363140T3 (da) | Antisekretorisk protein til anvendelse i behandlingen af kompartmentsyndrom | |
| US8487074B2 (en) | Modulation of lipid rafts | |
| DK2934564T3 (da) | Antisekretionsfaktor (af) til anvendelse i behandlingen af glioblastom | |
| Bajek et al. | Influence of hyperbaric oxygen treatment on myogenic transcriptional factors of denervated rat muscle |